Ceftobiprole also was found to clinically cure more than 90% of patients who had infections caused by Staphylococcus aureus, including patients with complicated skin infections due to PVL-positive methicillin-resistant S. aureus (MRSA), according to results from late-stage studies.
Data from the Phase III trials demonstrated that 500mg of ceftobiprole administered intravenously every eight hours, (500mg IV q8h) was as effective and well tolerated as the commonly used combination of 1g of vancomycin administered intravenously every 12 hours, (1g IV q12h) plus 1g of ceftazidime administered intravenously every eight hours, (1g IV q8h) in eradicating a broad spectrum of gram-positive and gram-negative bacteria associated with complicated skin infections, including diabetic foot infections.
Gary Noel, study author and Franchise Medical Leader, Anti-Infectives for Johnson & Johnson, said: “These results demonstrate that ceftobiprole, as a single agent, may be as effective as commonly used combination therapy in treating a range of today's serious gram-negative and gram-positive infections, such as MRSA.”